
Carisma Therapeutics Investor Relations Material
Latest events

Q2 2025
27 Aug, 2025

Q1 2025
12 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Carisma Therapeutics Inc
Access all reports
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies using its proprietary macrophage and monocyte cell engineering platform. The company's primary aim is to create treatments for cancer and other serious diseases by leveraging engineered macrophages and monocytes to attack and eliminate tumor cells. Carisma's product candidates include ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) and CAR-macrophage (CAR-Macrophage) cellular therapies designed to treat solid tumors that overexpress specific markers such as HER2. The company is headquartered in Philadelphia, PA, and its shares are listed on the NASDAQ.
Key slides for Carisma Therapeutics Inc


H.C. Wainwright 26th Annual Global Investment Conference 2024
Carisma Therapeutics Inc


H.C. Wainwright 26th Annual Global Investment Conference 2024
Carisma Therapeutics Inc
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
CARM
Country
🇺🇸 United States